Outlook Therapeutics, Inc. — Net Income by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/87a2bce5-ba3a-4a77-9242-f69d2771dd48/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-62.4M | 2024-10-01 – 2025-09-30 | evidence 0001104659-25-123264 |
| FY 2024 | $-75.4M | 2023-10-01 – 2024-09-30 | evidence 0001558370-24-016491 |
| FY 2023 | $-59.0M | 2022-10-01 – 2023-09-30 | evidence 0001558370-23-020000 |
| FY 2022 | $-66.1M | 2021-10-01 – 2022-09-30 | evidence 0001558370-22-019036 |
| FY 2021 | $-53.2M | 2020-10-01 – 2021-09-30 | evidence 0001558370-21-017007 |
| FY 2020 | $-35.2M | 2019-10-01 – 2020-09-30 | evidence 0001558370-20-014540 |
| FY 2019 | $-34.5M | 2018-10-01 – 2019-09-30 | evidence 0001104659-19-074095 |
| FY 2018 | $-30.1M | 2017-10-01 – 2018-09-30 | evidence 0001144204-18-065142 |
| FY 2017 | $-38.8M | 2016-10-01 – 2017-09-30 | evidence 0001571049-17-008779 |
| FY 2016 | $-53.3M | 2015-10-01 – 2016-09-30 | evidence 0001571049-17-008779 |
| FY 2015 | $-47.4M | 2014-10-01 – 2015-09-30 | evidence 0001571049-16-020882 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Outlook Therapeutics, Inc. — all facts · Revenue · Operating Income